{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-196582","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2022-07-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.813645+00:00","generated_at":"2026-06-24T12:26:47.808883+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Amneal subsidiary settles Opana ER antitrust litigation for $265M; records Q2 charge","bullets":["Impax subsidiary agrees to pay $265M plus interest to settle Opana ER antitrust class actions.","Settlement covers direct purchaser, indirect purchaser, and individual claims in MDL.","Company to record pre-tax charge of approx. $265M in Q2 2022.","Payments to be made between 2022 and Jan 2024; funded by cash on hand, cash flow, and revolver.","Settlement is not an admission of liability; subject to court approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-196582","json":"https://secwatch.observer/filing/0001193125-22-196582.json","markdown":"https://secwatch.observer/filing/0001193125-22-196582.md","text":"https://secwatch.observer/filing/0001193125-22-196582.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000119312522196582/0001193125-22-196582-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000119312522196582/d320133d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T12:26:47.808883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}